

Accepted Manuscript

Biological evaluation of microbial toxin degradation by microinjected zebrafish (*Danio rerio*) embryos

Zsolt Csenki, Edina Garai, Anita Risa, Mátyás Cserhádi, Katalin Bakos, Dalma Márton, Zoltán Bokor, Balázs Kriszt, Béla Urbányi



PII: S0045-6535(19)30660-5

DOI: <https://doi.org/10.1016/j.chemosphere.2019.04.014>

Reference: CHEM 23522

To appear in: *ECSN*

Received Date: 4 February 2019

Revised Date: 1 April 2019

Accepted Date: 2 April 2019

Please cite this article as: Csenki, Z., Garai, E., Risa, A., Cserhádi, Máá., Bakos, K., Márton, D., Bokor, Zoltá., Kriszt, Balá., Urbányi, Bé., Biological evaluation of microbial toxin degradation by microinjected zebrafish (*Danio rerio*) embryos, *Chemosphere* (2019), doi: <https://doi.org/10.1016/j.chemosphere.2019.04.014>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Biological evaluation of microbial toxin degradation by microinjected zebrafish (*Danio***
2 ***rerio*) embryos**

3

4 Zsolt Csenki ^{1†*}, Edina Garai^{1†}, Anita Risa², Mátyás Cserhádi², Katalin Bakos¹, Dalma
5 Márton², Zoltán Bokor¹, Balázs Kriszt², Béla Urbányi¹

6

7 ¹*Department of Aquaculture, Institute of Aquaculture and Environmental Safety, Faculty of*
8 *Agricultural and Environmental Sciences, Szent István University, 1. Páter Károly St., H-*
9 *2100 Gödöllő, Hungary*

10 ²*Department of Environmental Safety and Ecotoxicology, Institute of Aquaculture and*
11 *Environmental Safety, Faculty of Agricultural and Environmental Sciences, Szent István*
12 *University, 1. Páter Károly St., H-2100 Gödöllő, Hungary*

13 † The authors contributed equally to this work

14 *Address correspondence to: Zsolt Csenki csenki.zsolt@mkk.szie.hu

15

16 Declarations of interest: none

17

18

19 **Abstract**

20 The use of microinjection of newly fertilized zebrafish eggs as an appropriate tool for
21 qualifying the biotransformation properties of toxin-degrading microbes was investigated.

22 Ochratoxin A (OTA), bacterial degradation products of OTA and bacterial metabolites of the
23 *Cupriavidus basilensis* ÖR16 strain were microinjected. Results showed that variations in the

24 injected droplet size, and thus treatment concentrations, stayed within $\pm 20\%$, moreover
25 embryo mortality did not exceed 10% in controls, that is in accordance with the

26 recommendations of the OECD 236 guideline. The highest lethality was caused by OTA with
27 a significantly higher toxicity than that of bacterial metabolites or OTA degradation products.

28 However, toxicity of the latter two did not differ statistically from each other showing that the
29 observed mortality was due to the intrinsic toxicity of bacterial metabolites (and not OTA

30 degradation products), thus, the strain effectively degrades OTA to nontoxic products.
31 Sublethal symptoms also confirmed this finding.

32 Results confirmed that microinjection of zebrafish embryos could be a reliable tool for testing
33 the toxin-degrading properties of microbes. The method also allows comparisons among

34 microbial strains able to degrade the same toxin, helping the selection of effective and
35 environmentally safe microbial strains for the biotransformation of mycotoxins in large scale.

36 **Keywords:** *Cupriavidus basilensis*, mycotoxin, ochratoxin, biodegradation, biotransformation

37

38 1. Introduction

39 Ochratoxin A (OTA) is a hazardous mycotoxin produced during the secondary metabolism of
40 filamentous fungi belonging to the genera *Aspergillus* and *Penicillium* (Bui-Klimke and Wu,
41 2015). OTA is a potent nephrotoxic mycotoxin that has several harmful effects in Vertebrates,
42 including fish, such as hepatotoxicity (Gagliano et al., 2006), teratogenicity (Haq et al., 2016;
43 O'Brien et al., 2005) and immunosuppression (Marin and Taranu, 2015). OTA has been
44 reported to play a role in the development of different types of tumors in Rodent models and
45 humans (Pfohl-Leszkowicz and Manderville, 2007). Chronic OTA exposure proved to be a
46 leading factor in mycotoxin-induced porcine nephropathy and Balkan endemic nephropathy
47 (BEN) in humans (Stoev and Denev, 2013; Vrabcheva et al., 2000).

48 The toxin is present in various agricultural products (e.g., fruits, cereals, meats, coffee beans,
49 spices) (Bui-Klimke and Wu, 2015) and survives many common food-processing procedures,
50 such as roasting, brewing and baking, thus, it can be found in bread (Scudamore et al., 2004),
51 juicy fruits (Fernández-Cruz et al., 2010), beer (Odhav and Naicker, 2002) and wine
52 (Otteneder and Majerus, 2000). Because of its potential health risks, many countries and
53 international organizations have introduced a limit value for the OTA content of cereals and
54 cereal products (ECR, 2006; FAO, 2003).

55 Global occurrence of mycotoxins in the food chain is a problem worldwide, so several
56 strategies have been developed to decrease mycotoxin levels in animal feeds and human food
57 e.g. prevention, physical and chemical methods and biodegradation (Binder, 2007; EFSA,
58 2010). Among these, toxin biodegradation by microorganisms or their enzymes is the most
59 promising approach which could be an important postharvest strategy to reduce or eliminate
60 mycotoxin contamination.

61 There is growing need for the selection of microbial strains for efficient mycotoxin
62 biodegradation in large scale use, which are able to eliminate the hazardous effects of a toxin

63 and its breakdown products in addition to the degradation of their chemical structure
64 (Ferenczi et al., 2014; Sheikh-Zeinoddin and Khalesi, 2018; Vanhoutte et al., 2016).
65 Traditional analytical and immunological methods are sufficient to test biodegradation of the
66 parent compound, but they are unable to detect the toxic effects of potential degradation
67 products and bacterial metabolites. In addition, biodegradation does not always mean
68 biotransformation. According to the statements described above and the scientific advice of
69 EFSA (EFSA, 2010), it is important to develop and use new *in vivo* toxicological approaches
70 for investigating biodegradation and detoxification efficiency directly.

71 Various microorganisms have been reported to be suitable for degrading and detoxifying
72 OTA, some of them are highly efficient (Abrunhosa et al., 2014; Hathout and Aly, 2014).
73 Two pathways may be involved in OTA microbiological degradation. The primary is the
74 hydrolytic cleavage of the amide bond in OTA, resulting in the production of phenylalanine
75 and ochratoxin α (OT α), which - in most cases - is the major degradation product. Since OT α
76 and phenylalanine are presumably non-toxic, this mechanism can be considered as a
77 detoxification pathway. The second is a hypothetical process where OTA is degraded via the
78 hydrolysis of the lactone ring (Karlovsky Petr, 1999). In this case, the final degradation
79 product is an opened lactones form of OTA, which has similar toxicity to the parent
80 compound (Li et al., 1997; Xiao et al., 1996).

81 In the present report, *Cupriavidus basilensis* (ÖR16 strain), the first *Cupriavidus* species with
82 proven OTA degradation potency has been selected. The strain ÖR16 can degrade almost
83 100% of OTA in solutions with concentrations below 20 mg/L in laboratory conditions
84 during 5 days of incubation, and the major metabolite of OTA is OT α . The degradation
85 efficiency of the strain was tested in mice, where neither the metabolites produced in a
86 modified LB medium, nor the degraded OTA residuals evoked pathological disorders, or
87 disturbed the expression of the examined genes (Ferenczi et al., 2014). Based on these

88 phenomena, the strain ÖR16 seems to be suitable for developing new *in vivo* test methods for
89 Vertebrate models to examine and evaluate the detoxification ability of mycotoxin degrading
90 microorganisms.

91 Zebrafish embryo tests are widely used bioassays in toxicological and ecotoxicological
92 testing, and are often used to analyze organic-matter rich samples (e.g. waste water and
93 sediment samples) (Braunbeck et al., 2005; Nagel, 2002). Since these assays should be carried
94 out at temperatures above 25°C, many factors may interfere with toxicity evaluation, of which
95 low oxygen supply in the embryo test vessel is one of the most important (Küster and
96 Altenburger, 2008; Strecker et al., 2011). Deviations from oxygen saturation increase the
97 frequency of malformations or suspension of embryo development, and distinction between
98 effects of hypoxia and the toxicity of a sample is not always possible. For organic-matter rich
99 samples, the microinjection of fish embryos could be an alternative method to eliminate the
100 secondary effects of hypoxia.

101 Microinjection is a simple way to introduce substances into newly fertilized fish eggs. It has
102 previously been used for testing polar and nonpolar substances in many fish species (Colman
103 et al., 2004; Mizell and Romig, 1997; Walker et al., 1992). Effects on embryonic development
104 are visible shortly after microinjection, and even minor toxic effects can be distinguished
105 from background mortality and other sublethal symptoms. Although, microinjection of
106 substances into the yolk of zebrafish eggs is feasible, introduction of accurate volumes (e.g.
107 constant volumes) through a series of injections seems to be problematic so nominal and real
108 injected volumes may be different (Schubert et al., 2014).

109 The objective of this *in vivo* toxicological study was to investigate whether microinjection of
110 newly fertilized zebrafish eggs could be an appropriate tool for qualifying the
111 biotransformation efficiency of toxin-degrading microbes. Therefore OTA, breakdown
112 products of OTA and bacterial metabolites of *Cupriavidus basilensis* ÖR16 strain were

113 injected into zebrafish eggs at different volumes and mortality and sublethal effects were
114 compared. Additionally, we investigated the injected volume fluctuations during a series of
115 microinjections, to see if desired treatment concentrations are reached and to ensure that the
116 results are reliable.
117

ACCEPTED MANUSCRIPT

118 2. Material and methods

119 2.1. Animal protection

120 The Animal Protocol was approved under the Hungarian Animal Welfare Law (XIV-I-
121 001/2303-4/2012).

123 2.2. Zebrafish maintenance and egg collection

124 Laboratory-bred AB strain zebrafish were held in breeding groups of 30 females and 30 males
125 at the Department of Aquaculture, Szent István University, Hungary, in a Tecniplast ZebTEC
126 recirculation system (Tecniplast S.p.A., Italy) at $25.5^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$, pH 7.0 ± 0.2 , conductivity
127 $550 \pm 50 \mu\text{S}$ (system water) and light:dark period of 14 h:10 h. Fish were fed twice a day with
128 dry granulate food (Zebrafeed 400-600 μm , Sparos Lda., Portugal) supplemented with freshly
129 hatched live *Artemia salina* twice a week. Fish were placed in breeding tanks (Tecniplast
130 S.p.a.) late in the afternoon the day before the experiment and allowed to spawn by removing
131 the dividing walls next morning. Spawning of individual pairs was delayed through time to
132 allow a continuous supply of 1-cell embryos.

134 2.3. Bacterial strain cultivation and metabolite preparation

135 The bacterial *Cupriavidus basilensis* ÖR16 strain (stored at -80°C) was thawed on ice,
136 streaked on Luria-Bertani (LB) agar plates (10 g tryptone, 5 g yeast extract, 9 g sodium-
137 chloride and 18 g bacteriological agar (Biolab Ltd., Hungary) in 1L (pH 7.0) ion-exchanged
138 water) and incubated at 28°C for 72 hours. Then single colonies were inoculated into 50 mL
139 100% LB medium (10 g tryptone, 5 g yeast extract and 9 g sodium-chloride in 1L (pH 7.0)
140 ion-exchanged water) in 250 mL flasks and cultures were grown for 120 h at 28°C , 170 rpm
141 in a shaking incubator (Sartorius Certomat BS-1, Germany). Liquid cultures were centrifuged
142 at 3220 g, 4°C for 20 min (Eppendorf 5810R, Germany), the pellet was resuspended in 50

143 mL 20% LB medium (100% LB medium diluted with ion-exchanged water), then was
144 centrifuged again at the same conditions. The procedure was repeated twice. After
145 resuspension, the optical density of the culture was measured at 600 nm (OD_{600}) (GENESIS
146 10S UV-VIS, Thermo Fischer Scientific) and adjusted to 0.6 ± 0.05 to prepare bacterial
147 inoculum. 5 mL bacterial suspensions were inoculated into 45 mL sterile 20% LB medium in
148 triplicates and incubated on a laboratory shaker at 28 °C, 170 rpm for 120 h. Cultures were
149 then centrifuged at 3220 g, 4 °C, for 15 min. Supernatants were filtered through 0.2 μ m
150 syringe filters (VWR International Ltd., Hungary) to gain bacteriologically sterile samples
151 containing bacterial metabolites only. Samples were stored at -20 °C until microinjection.

152

153 *2.4. Ochratoxin A biodegradation and OTA concentration measurement*

154 Bacterial inocula (5 mL) were prepared as above, and added to 45 mL 20% LB medium
155 containing OTA (7 mg/L final concentration). Similar inocula were prepared in parallel
156 without OTA to test the effects of bacterial metabolites. Uninoculated LB medium (20%)
157 contaminated by OTA (7 mg/L) was used as negative control. Both of the cultures and control
158 were incubated at 28 °C, 170 rpm for 120 h in triplicates. After the incubation, cultures were
159 centrifuged at 3220 g, 4 °C, for 20 min. Supernatants were filtered with 0.2 μ m syringe filters,
160 and samples were stored at -20 °C until microinjection.

161 For the measurement of OTA concentration, high-performance liquid chromatography with
162 tandem mass spectrometry (HPLC-MS/MS) was applied. Prior to measuring toxin
163 concentration, 100 μ L sample were mixed with 25 μ L isotope-labelled internal standard ($^{13}C_{20}$ -
164 OTA), the mixture was evaporated under nitrogen gas, thereafter it was reconstituted in 50-50
165 V/V% A-B eluent (A : water, 5mM ammonium-acetate, 0.1% acetic acid ; B : methanol,
166 5mM ammonium-acetate, 0.1% acetic acid). For the separation Agilent 1100 HPLC (Agilent
167 Technologies, USA) equipped with Agilent Zorbax C18 column (3.5 μ m, XDB-C18, 2.1 x

168 50mm) was used. 10 μL prepared samples were injected into the mobile phase containing A-
169 B eluent. 400 $\mu\text{L}/\text{min}$ flow rate and 40°C column temperature was set. 3200 QTRAP
170 LC/MS/MS system (Applied Biosystems, USA) in positive ion mode was used for the
171 determination of OTA concentration in samples. During the measurement, LOD was 2 $\mu\text{g}/\text{L}$
172 and LOQ was 6 $\mu\text{g}/\text{L}$.

173 2.5. Microinjection

174 A Narishige (Japan Model PN-31) micropipette puller (heater level: 89.1, magnet sub level:
175 15.7, magnet main level: 84.3) was used to pull microinjection pipette tips (injection needle)
176 (Narishige Japan G-1 borosilicate glass capillary, 1 mm o.d. x 0.6 mm i.d., 90 mm length).
177 Injection needles were backfilled with 20 μL substance without air bubbles by a Microloader
178 pipette tip (Eppendorf, Germany).

179 The needle was placed in the microinjection manipulator (microINJECTOR MINJ-2, TriTech
180 Research Inc. Los Angeles, USA) connected to a nitrogen gas bottle. Injections were carried
181 out under a stereomicroscope at 15 \times magnification (Leica LED2500, Leica Microsystems
182 GmbH, Germany). Injection volumes were determined in immersion oil (Merck Ltd.,
183 Hungary, An affiliate of Merck KGaA, Darmstadt, Germany) on the basis of droplet
184 diameters by a calibrated software (Leica M205 FA, Leica DFC 7000T camera, Leica
185 Application Suite 3.4.2.18368, Leica Microsystems GmbH, Germany). Injection volumes
186 were administered five times into the oil droplet until appropriate volume was achieved
187 (pressure or capillary orifice size change). According to the sphere volume formula

3

188 ($V=1/6\pi d^3$), a sphere diameter of 50 μm corresponded to an injection volume of 0.22 nL, 100
189 μm to 0.52 nL, 150 μm to 1.77 nL, and 200 μm to 4.17 nL. Injection volume needed to be
190 measured and adjusted for each solution, concentration and control.

191 One-cell stage zebrafish embryos were lined up against the side of a microscope slide placed
192 in a 10 cm diameter Petri dish. Excess water was removed with a plastic pipette. Treatment
193 groups of 20 eggs were injected in a minimum of three replicates per treatment. Following
194 microinjection, eggs were incubated in system water with methylene blue (2 mL 0.1%
195 methylene blue in 1 L system water) ($25^{\circ}\text{C} \pm 2^{\circ}\text{C}$) in 10 cm diameter Petri dishes. After 2
196 hours, coagulated and/or non-fertilized eggs were discarded and developing embryos were
197 transferred in groups of twenty into 6 cm diameter Petri dishes. Embryos were then incubated
198 in system water at $26^{\circ}\text{C} \pm 1^{\circ}\text{C}$ and a 14 h:10 h-light:dark period and checked for lethal and
199 sublethal effects under a microscope. System water was replaced in every 24 hours until 120
200 hpf (hours post-fertilization). Digital images of embryos (72 hpf) and larvae (120 hpf) in
201 lateral orientation were taken under a stereomicroscope at 30 \times magnification (Leica M205
202 FA, Leica DFC 7000T camera, Leica Application Suite 3.4.2.18368, Leica Microsystems
203 GmbH, Germany).

204

205 *2.6. Determination of the variations in the injection volume*

206 Zebrafish Ringer's solution (ZFR) (116 mM sodium-chloride, 2.9 mM potassium-chloride,
207 1.8 mM calcium-chloride and 5 mM HEPES (pH 7.2) (Sigma-Aldrich, Hungary) in system
208 water, filtered with 0.2 μm syringe filters) was injected into the yolk of zebrafish eggs. Prior
209 to treatments, microinjection parameters (pressure and capillary orifice size) were set
210 according to the volumes calculated on the basis of injected droplet sizes in immersion oil.
211 When the desired volume was reached, five eggs were injected, and the diameter of five
212 droplets was measured again in immersion oil. This egg injection - droplet measurement cycle
213 was repeated five times to test the accuracy of injection.

214

215 2.7. *Effect of the highest used injection volume and the LB media on the viability of*
216 *embryos*

217 The effect of the largest injection volume (4.2 nL) on egg viability was tested with Zebrafish
218 Ringer's solution, the negative control of the experiments. The effect of the bacterial growth
219 medium and the effects of the solvent were tested following the injection of 4.2 nL of 20%
220 LB medium and 20% LB medium with acetone (250 µL acetone in 50 mL 20% LB medium).

221

222 2.8. *Determination of the initial OTA concentration of the reference curve*

223 OTA (99.5% Fermentek, Israel) was dissolved in acetone (98.8% Sigma-Aldrich, Hungary) at
224 1000 mg/L concentration, of which 1; 7; 10 mg/L concentrations were prepared in 20% LB
225 medium. OTA contaminated medium was injected in 0.22 nL, 0.52 nL, 1.77 nL and 4.17 nL
226 volumes into the embryos to find the optimal concentration for the reference curve.

227

228 2.9. *Examining the toxicity of samples derived from OTA degradation experiment*

229 Samples containing ÖR16 metabolic products as well as OTA degradation products were
230 injected in 0.22 nL, 0.52 nL, 1.77 nL and 4.17 nL volumes into the zebrafish embryos.

231

232 2.10. *Examination of injected embryos*

233 Embryo mortality was determined at 72 and 120 hpf on the basis of egg coagulation, the lack
234 of somite formation and the lack of heart function. Sublethal effects were examined at 72 and
235 120 hpf, the endpoints were pericardial edema, yolk edema, tail deformation, craniofacial
236 deformation and disintegrated abnormal embryo shape. Abnormalities were recorded
237 separately, irrespective of the number of deformities per individual.

238

239 *2.11. Statistics*

240 Results were analysed and graphs were plotted by GraphPad Prism 6.01 (GraphPad Software,
241 San Diego, USA). Data were checked for normality with Shapiro-Wilk normality test and
242 non-compliance with the requirements of parametric methods was established. Significant
243 differences were verified by Kruskal-Wallis analysis with Dunn's multiple comparisons test.

244

3. Results and discussion

3.1 Examination of variations in the microinjection volume

In toxicology including ecotoxicology, the concentrations used should remain as stable as possible to obtain reliable results. The microinjection method may cause volume fluctuations, the rate of which depends on the injection time, the applied pressure, the diameter of the needle tip and the viscosity of the cytoplasm of the injected cell (Minaschek G. et al., 1989; Schubert et al., 2014). These volume variations cause concentration shifts, and so nominal and real concentrations may differ from each other.

The best method for volume determination is the measurement of droplet diameters in the yolk after each injection (Schubert et al., 2014). However, with diffuse substances – such as those used in these experiments – this is not possible, therefore droplet size was measured in immersion oil, prior to microinjection to the yolk. To examine alterations in the injection volume during the microinjection procedure, a microinjection series was carried out with zebrafish Ringer's solution and the diameter of injected droplets were measured after the injection of every 5 embryos. In general, no significant difference was observed between replicates compared to the desired diameter (Fig 1 A). Minimal and maximal droplet volumes calculated from the measured diameters are shown in Fig 1 B. The largest decrease in volume was detected in case of the 1.77 nL droplet size (17.51% (1.46 nL)), while the largest volume increase was seen in case of the 0.22 nL droplet size (18.18% (0.26 nL)).

According to the OECD 236 guideline for the Fish Embryo Toxicity Test, nominal and real concentrations should not differ from each other by more than $\pm 20\%$ (OECD236, 2013). In this experiment deviations from the nominal volume stayed within this range for all volumes tested, thus presumably our experiments would meet this basic requirement.

269 Results show that with the above described experimental settings, the method is
270 dimensionally stable for all used droplet sizes, if the capillary is not clogged during injection.

271

272 *3.2 Effect of the largest injection volume and the media on the viability of embryos*

273 Prior to testing bacterial products, potential toxic effects of three basic media, the Zebrafish
274 Ringer's solution, the LB medium, the medium supplemented with the solvent acetone (which
275 served as a bacterial propagation medium and carrier for OTA) and the largest used injection
276 volume (selected according to the work of Schubert and co-workers (2014)) was examined.

277 The injection volume is a critical factor in postinjection embryo survival, but potentially does
278 not cause egg trauma if the administered volume is bellow 10% of the total volume of the
279 yolk (Walker et al., 1992). For the same substance and same concentration, smaller injection
280 volumes cause less mortality and malformations in injected embryos (Zabel et al., 1995).

281 According to these, LB media were administered in the largest droplet volume too.

282 As the conditions did not have significant toxic effects, only results for 5 days of exposure are
283 shown in Figure 1 C. In the non-injected control no dead embryos were found, and the
284 average mortality rate was also very low in case of the LB medium (5%), the solvent
285 supplemented LB (5%) and the ZFR (5.83%) and there was no significant difference between
286 treatments. Malformations were not detected either in injected or non-injected (control)
287 embryos (Fig. 1 D).

288 The OECD guideline for fish embryo test allows a maximum of 10% lethality in the control
289 during an experiment (OECD236, 2013). This criterion was fulfilled in this study, since LB
290 media and ZFR caused lower lethality. Based on the mortality and morphology results, the
291 injection settings and droplet sizes used here seemed to be suitable for further work, the
292 examined conditions are not toxic to zebrafish embryos and so do not affect the outcome of
293 subsequent tests.

294

295 *3.3 The effect of metabolites produced by the Cupriavidus basilensis ÖR16 strain on the*
296 *survival of microinjected embryos*

297 Bacterial metabolites produced during the primary metabolism of the strain (ÖR16) might
298 also have toxic effects on embryos, therefore the effect of the LB medium following 3 and 5
299 days of bacterial incubation was tested in 4 injection volumes (Fig. 2 A and B). The solution
300 decreased the survival rate of embryos at 72 and 120 hpf too and dose-response relationship
301 was found between injection volumes and lethality. After 72 hours of exposure, significant
302 increase was detected in mortality in the groups injected with 1.77 and 4.17 nL ($p < 0.05$)
303 compared to the control, and the group injected with the largest volume (4.17 nL) and the
304 group injected with 0.22 nL ($p < 0.01$). Mortality in the groups injected with the two largest
305 volumes was 22.92% (1.77 nL) and 26.15% (4.17 nL), with no significant difference between
306 the groups. Mortality increased in all injected groups after 120 hours of exposure, but
307 compared to the control, significant difference was only detected in the groups injected with
308 the two largest volumes where mortality was 32.92% (1.77 nL, $p < 0.01$) and 50.13% (4.17
309 nL, $p < 0.01$). Results clearly show that the strain ÖR16 produces toxic metabolites that –
310 following administration by microinjection – decrease the survival of zebrafish embryos.
311 Ferenczi et al. (2014) examined OTA biodegradation efficiency of the strain ÖR16 and the
312 toxicity of breakdown products derived from degradation in feeding experiments with mice.
313 Animals were exposed to ÖR16 metabolites via intragastric gavage once a day through 21
314 days. Toxic effects were examined via the expression of several marker genes and
315 histopathological examination of the kidney and spleen. In mice, metabolic products of the
316 strain ÖR16 did not seem to be toxic compared to the control. According to the results
317 described above, zebrafish embryos seem to be more sensitive to the bacterial metabolites
318 than mice, however, difference may be due to different exposition pathways.

319

320 *3.4 Determination of the initial OTA concentration for further experiments*

321 In order to determine the initial OTA concentration for further degradation experiments, OTA
322 was injected into the yolk of embryos in 1, 7 and 10 mg/L concentration, in different volumes.

323 All concentrations fell within the degradable concentration range of strain ÖR16. Mortality
324 was checked at 3 and 5 dpf and results were plotted on a dose response curve for mortality.

325 The graph of the potentially optimal initial concentration should serve as a reference for
326 further experiments even if toxicity is higher following degradation, so should meet the
327 following requirements: the maximum mortality should not exceed that of the bacterial
328 metabolic products and the curve should not reach its maximum early.

329 Mortality increased along with the injection volume in case of all three OTA concentrations,
330 and reached the maximum after 72 hours of exposure in all cases. Mortality did not change
331 significantly for 120 hours following exposure (Fig. 3 A and B).

332 The slope of the dose-response curve for 1 mg/L OTA was lower than the others and
333 mortality maximum was reached only with the largest injection volume following 72 and 120
334 hours of exposure. In case of lower injection volumes, mortality was below 10%.

335 Dose-response relationship was detected between injection volumes and mortality in case of 7
336 mg/L OTA as well. Mortality increased gradually with injection volumes at 72 and 120 hours
337 of exposure too, and the maximum (100%) was reached with the largest injection volume.

338 From 0.52 nL, significant difference ($p < 0.05$) was detected in mortality compared to the
339 control. Differences between mortality values of the groups injected with volumes ≤ 0.52 nL

340 compared to the 1.77 ($p < 0.001$) and 4.17 nL injection volumes were also significant ($p <$
341 0.05), however, no significant difference was found in case of the two largest volumes (Fig.

342 3C and D). Mortality reached its maximum (75%) early with 10 mg/L OTA with the lowest
343 injection volume (0.52 nL) and did not show to be higher with larger volumes.

344 On the basis of our results, 7 mg/L was selected to be an initial concentration in further
345 experiments. The mortality curve of this concentration shown here served as reference for
346 subsequent tests.

347 The present study was the first to examine acute toxic effects of OTA following
348 microinjection, and high mortality was detected even after short exposures to low
349 concentrations. However, these results are difficult to compare to the results of classical tests
350 where embryos are exposed via waterborne exposure. It is still unclear how substances are
351 distributed in the yolk following injection but it is inhomogenous in most cases, so
352 presumably embryos are not exposed uniformly. Moreover, zebrafish embryos consume their
353 yolk sac completely to 165 ± 12 hpf (Litvak and Jardine, 2003), thus, some of the substance
354 may remain unabsorbed during the exposition period presented here, however, with longer
355 exposure the experiment would fall under animal testing regulations. The microinjection
356 technique enables the administration of exact amounts, so theoretically it would be possible to
357 determine doses per bodyweight as seen in feeding experiments with vertebrates.

358

359 *3.5 Toxicity of samples derived from ochratoxin degradation experiment*

360 In order to clarify the toxicity of OTA-metabolites produced during microbial toxin
361 degradation with strain ÖR16, degradation products were microinjected in four concentrations
362 into zebrafish embryos. Mortality was examined on the 3rd and 5th day of exposure.

363 Mortality increased with the injected volume as seen previously. At 72 hours of exposure,
364 mortality in the non-injected control, and in the 0.22 nL and 0.52 nL injection volumes was
365 below 10%, and did not reach 30% even with the highest volumes. No significant difference
366 was observed between treated groups (Fig. 4 B). At 120 hours of exposure, dose-response
367 relationship was found between the injected volume and embryo mortality, as mortality
368 increased gradually along with the injection volume and reached 38.5% in the largest volume.

369 Statistically significant decrease was detected in the number of survivals in the groups
370 injected with 0.52 nL, 1.77 nL and 4.17 nL compared to the non-injected control ($p < 0.05$),
371 and the two largest injection volumes compared to 0.22 nL ($p < 0.05$) (Fig. 4 C).

372 OTA degrading efficiency of strain ÖR16 was tested prior to exposure and it was found to be
373 95.6% (Fig. 4 A). OTA degradation of the strain ÖR16 is possibly mediated by a peptidase
374 enzyme. Ferenczi et al. (2014) showed that the major metabolite of OTA degraded by strain
375 ÖR16 is ochratoxin alpha (OT α). They found that OTA content in the supernatants decreased
376 gradually, OT α content increased in parallel during the 5-day incubation period and OTA was
377 completely degraded (94% decrease was measured by ELISA and 100% by HPLC), that is in
378 accordance with the results of the above described experiments. OT α is not potentially toxic,
379 according to the results of previous Vertebrate studies (Bruinink, 1998; Ferenczi et al., 2014).
380 Haq and co-workers (2016) tested the toxicity of OT α with ZETA test on zebrafish embryos
381 in concentrations ≤ 2.5 μM . In contrast to OTA, no significant difference was detected
382 between the mortality of embryos exposed to OT α and the untreated negative controls during
383 the 5 days exposure. On the basis of these, mortality in our experiments is probably due to
384 other metabolites of strain ÖR16.

385 Ferenczi et al. (2014) also studied OTA degradation products of strain ÖR16 in mouse
386 feeding experiments. Subchronic exposure did not cause mortality in mice and physiological
387 or gene expression alterations in the examined organs, compared to controls. However
388 degradation products were lethal to injected zebrafish embryos, so the zebrafish embryo is
389 probably a more sensitive model, than the mouse.

390

391 *3.6 Comparison of mortality values of 7 mg/L OTA, and the bacterial and degradation*
392 *products of the strain ÖR16*

393 Mortality caused by 7 mg/L OTA, and the bacterial and degradation products of the strain
394 ÖR16 were plotted on joint graphs. In order to investigate the degradation characteristics of
395 the bacterial strain, mortality values of equal volumes were compared to each other (Fig. 5 A
396 and B).

397 Following 72 hours of incubation, mortality did not show significant difference between
398 groups injected with the smallest volumes. In case of larger volumes, there was no difference
399 between results of the bacterial metabolites and the degradation products of the strain,
400 however, mortality values of 7 mg/L OTA differed significantly from these ($p < 0.05$).
401 Highest mortality was caused by 7 mg/L OTA injected in 0.52 nL and above.

402 120 hours after microinjection, no significant difference was seen between the mortality
403 values of groups injected with 0.22 nL. In case of the groups injected with 0.52 nL, significant
404 difference was detected between 7 mg/L OTA and the metabolites of the strain ÖR16 ($p <$
405 0.05). Mortality values of the degradation products of strain ÖR16 did not differ nor from that
406 of the bacterial metabolites neither from the OTA solution. In larger volumes, only mortality
407 values of 7 mg/L OTA differed significantly from other groups ($p < 0.001$ - degradation
408 products, $p < 0.01$ – ÖR16 bacterial metabolites), however, bacterial metabolites of the strain
409 and degradation products of OTA did not show significant difference. The highest mortality
410 was detected in 7 mg/L OTA injected in 0.52 nL and above.

411 As no statistical difference was found between the mortality values of the bacterial and
412 degradation products, it can be concluded that OTA breakdown products are not toxic, and
413 mortality is probably caused by metabolites of the strain ÖR16. Results also show that
414 exposure via microinjection is a potential, functional, alternative way to test the detoxification
415 efficiency of toxin degrading microbes on zebrafish embryos *in vivo*. Mortality in itself may
416 provide a sufficient endpoint when testing the differences between the toxicity of the bacterial
417 metabolites of a strain and the degradation products of the toxin following microinjection, and

418 toxicity of toxin degradation products can be predicted. There was no detectable difference
419 between the mortality curves of 3 and 5 days of exposure, so it seems that a 3 days exposure
420 period is sufficient for studying the degradation characteristics of bacterial strains.

421

422 *3.7 Sublethal effects in injected embryos*

423 Beyond mortality, sublethal endpoints were also analyzed in treated embryos following 72
424 and 120 hours of exposure. Generally, compared to the non-injected controls all treatments
425 with all injected volumes increased the frequency and severity of developmental deformities
426 (Fig. 6 A and B). Following 72 hours of exposure, the highest frequency of morphological
427 disorders was detected in the 7 mg/L OTA group, and in some replicates of treatments with
428 the highest volumes of this concentration, all surviving embryos showed abnormalities. A
429 statistically significant difference was only observed between the 1.77 nL OTA (7 mg/L), and
430 1.77 nL samples containing bacterial metabolites or degradation products ($p < 0.01$).
431 Following 120 hours of exposure, it was also evident that compared to other treatment groups
432 the ratio of deformed embryos was the highest in the groups treated with OTA from 0.52 nL
433 and above. Statistically significant differences were observed in ÖR16 bacterial metabolites
434 ($p < 0.01$) and breakdown products of OTA ($p < 0.05$) compared to 7 mg/L OTA, injected in
435 1.77 nL. Significant differences were also found between OTA 7 mg/L and metabolites of
436 strain ÖR16 ($p < 0.01$) or degradation products ($p < 0.05$), injected in 4.17nL. However no
437 significant difference was detected between the deformation frequencies in the groups
438 injected with the bacterial metabolites of the strain and OTA degradation products during the
439 whole exposure period with any injection volumes.

440 It can be concluded that notwithstanding the significant differences detected in morphology,
441 OTA degradation products seem to be nontoxic on the basis of deformation frequencies,
442 however the metabolites of the strain were proved to be toxic.

443 Figure 7. shows representative development dysfunctions in embryos from treatment groups
444 with statistically significant differences. Following 3 days of OTA injection (1.77 nL)
445 embryos displayed craniofacial deformities, small eyes, curvature of the body axis, yolk
446 deformities, reduced growth rates and edemas in some cases. Most of them have previously
447 been described in OTA treated zebrafish embryos (Haq et al., 2016), and teratogenic effect
448 was observed at sub-micromolar concentrations with an EC50 of 20 nM OTA.
449 Similarly to zebrafish OTA proved to be teratogenic in the amphibian *Xenopus laevis* model
450 (FETAX) too, causing mainly craniofacial deformities (O'Brien et al., 2005) like in the
451 experiments described above. These developmental abnormalities (craniofacial deformities)
452 were also detected in a wide range of Vertebrates, including rats (Brown and Purmalis, 1976),
453 mice (Arora, 1983), hamsters (Hood et al., 1976) and chicken (Wiger and Starrmer, 1990).
454 Decreased hatching rate described by Haq et al. (2016) was not seen in our experiments.
455 Embryos injected with the same volume (1.7 nL) of bacterial metabolites and OTA
456 degradation products displayed shorter body, yolk sac deformations, grey coloration in the
457 yolk, pericardial edema, small eyes and deformities of lower facial structures in embryos
458 following 3 days of injection. Curvation of the body as a common sign of OTA exposure has
459 not been detected.
460 Five days after microinjection, symptoms got more pronounced in OTA treated embryos and
461 severe deformations appeared all through the body. Embryos injected with bacterial
462 metabolites of the strain ÖR16 and OTA degradation products displayed shorter body, yolk
463 sac deformations, pericardial edema, edema around the abdomen, small eyes, small and not
464 well defined olfactory region and deformities of lower facial structures on the 5th day of
465 exposure. As in 3 dpf exposed embryos, curvation of the body axis was not seen here either.
466 In contrast, OT α did not seem to be toxic in Vertebrates. Haq and co-workers (2016)
467 examined the effects of OT α (along with OTA) on zebrafish embryos and neither

468 teratogenicity nor mortality differed significantly from that of the negative control embryos
469 during 5 days of exposure. Ferenczi *et al.* (2014) demonstrated apparent hydrolysis of OTA to
470 OT α , and consequent detoxification by using a bacterial species *Cupriavidus basilensis*, as
471 evidenced by comparative toxicological studies in a mouse model of nephrotoxicity.

472 In the present study, morphological examination showed that phenotype of OTA treated
473 embryos differed significantly from the morphology of embryos exposed to bacterial
474 metabolites or OTA degradation products in both experimental time points, however embryos
475 in the latter groups showed similar phenotypes. In conclusion, it seems that strain ÖR16
476 degrades OTA to nontoxic metabolites, the strain is able to degrade OTA even in 7 mg/L
477 concentration, and deformations resulted from the injection of OTA degradation products are
478 probably due to the metabolites of the bacteria. In addition, zebrafish exposed via
479 microinjection appeared to be more sensitive to the metabolites of strain ÖR16 than mice.

480 All injected solutions contained high levels of organic matter. No deformation implied
481 oxygen deprivation in morphological examinations of exposed zebrafish embryos (Küster and
482 Altenburger, 2008; Strecker *et al.*, 2011). Results suggest that microinjection can be an
483 alternative way to test samples with high organic matter content.

484 High organic matter content of samples often causes hypoxia during zebrafish embryo tests,
485 and its effects (developmental disorders, suspension of embryo development) can hardly be
486 differentiated from those of the sample itself (Küster and Altenburger, 2008; Strecker *et al.*,
487 2011). With microinjection hypoxic effect of such samples can be avoided and results can
488 easily be evaluated.

489

490

491 **4. Conclusions**

492 Microinjection is a simple way to introduce organic matter-rich test substances into newly
493 fertilized fish eggs and helps to eliminate hypoxia that cause a wide range of secondary
494 effects. If the method is well optimized, injection volume variations can be kept within $\pm 20\%$,
495 according to the OECD 236 test guideline's recommendations and so result reliability can be
496 ensured.

497 Results clearly showed that investigation of zebrafish embryos microinjected with toxin
498 solutions, metabolites of bacterial strains and OTA degradation products could provide an
499 alternative way for studying the toxin detoxification-properties of microbial strains. The
500 zebrafish embryo – thanks to their sensitivity – proved to be a good model for the studies.
501 Toxicity differences between substances may be detected even after 3 days of exposure on the
502 basis of mortality, that can be completed and further refined by the evaluation of sublethal
503 data.

504 Microinjection enables the selection of microbial strains that are able to degrade the toxin and
505 the identification of the most effective and environmentally safe microbes from the selected
506 strains.

507

508 **Acknowledgements**

509 This work was supported by Development and Innovation Fund (NKFIH); Grant Agreement:
510 NVKP_16-1-2016-0009 and VKSZ_12-1-2013-0078, EFOP-3.6.3-VEKOP-16-2017-00008
511 project co-financed by the European Union, and the Higher Education Institutional Excellence
512 Program (1783-3/2018/FEKUTSTRAT) awarded by the Ministry of Human Capacities within
513 the framework of water related researches of Szent István University. The scientific work of
514 Mátyás Cserhádi was supported by the János Bolyai Research Grant of the Hungarian

515 Academy of Sciences. Edina Garai was supported by the ÚNKP-18-3-I New National
516 Excellence Program of the Ministry of Human Capaticies. The authors gratefully thank Ákos
517 Horváth for critical reading of the manuscript.

518

ACCEPTED MANUSCRIPT

519

520 **5. References**

- 521 Abrunhosa, L., Inês, A., Rodrigues, A.I., Guimarães, A., Pereira, V.L., Parpot, P., Mendes-
522 faia, A., Venâncio, A., 2014. International Journal of Food Microbiology Biodegradation
523 of ochratoxin A by *Pediococcus parvulus* isolated from Douro wines. *Int. J. Food*
524 *Microbiol.* 188, 45–52. <https://doi.org/10.1016/j.ijfoodmicro.2014.07.019>
- 525 Arora, R.G., F.H.; Fellner, F.H., 1983. INHIBITION OF OCHRATOXIN A TERATO
526 GENESIS. *Food Chem. Toxicol.* 21, 779–783.
- 527 Binder, E.M., 2007. Managing the risk of mycotoxins in modern feed production 133, 149–
528 166. <https://doi.org/10.1016/j.anifeedsci.2006.08.008>
- 529 Braunbeck, T., Boettcher, M., Hollert, H., Kosmehl, T., Lammer, E., Leist, E., Rudolf, M.,
530 Seitz, N., 2005. Towards an alternative for the acute fish LC(50) test in chemical
531 assessment: the fish embryo toxicity test goes multi-species -- an update. *ALTEX* 22,
532 87–102. <https://doi.org/10.1007/s10811-007-9297-x>
- 533 Brown, M.H., Purmalis, B.P., 1976. Teratogenic and Toxic Effects of Ochratoxin A in Rats
534 fetal hemorrhage and an undefined defect termed “coelosomy,” they were unable to
535 detect any skeletal or visceral malformations. The present study was designed to further
536 assess the teratogenic poten. *Toxicol. Appl. Pharmacol.* 37, 331–338.
- 537 Bruinink, A., R.T., S.C., 1998. Differences in Neurotoxic Effects of Ochratoxin A, Ochracin
538 and Ochratoxin- a In Vitro. *Nat. Toxins* 177, 173–177.
- 539 Bui-Klimke, T.R., Wu, F., 2015. Ochratoxin A and Human Health Risk: A Review of the
540 Evidence. *Crit. Rev. Food Sci. Nutr.* 55, 1860–1869.
541 <https://doi.org/10.1080/10408398.2012.724480>
- 542 Colman, J.R., Dechraoui, M.Y.B., Dickey, R.W., Ramsdell, J.S., 2004. Characterization of
543 the developmental toxicity of Caribbean ciguatoxins in finfish embryos. *Toxicon* 44, 59–

- 544 66. <https://doi.org/10.1016/j.toxicon.2004.04.007>
- 545 ECR, 2006. Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting
546 maximum levels for certain contaminants in foodstuffs. Off J Eur Union 364 5–24.
- 547 EFSA, 2010. Statement on the establishment of guidelines for the assessment of additives
548 from the functional group ‘ substances for reduction of the contamination of feed by
549 mycotoxins ’ 1 EFSA Panel on Additives and Products or Substances used in Animal
550 Feed (FEEDA. EFSA J. 8, 1–8. <https://doi.org/10.2903/j.efsa.2010.1693>.
- 551 FAO, 2003. Food and Agriculture organization of the United Nations.
- 552 Ferenczi, S., Cserháti, M., Krifaton, C., Szoboszlay, S., Kukolya, J., Szoke, Z., Koszegi, B.,
553 Albert, M., Barna, T., Mézes, M., Kovács, K.J., Kriszt, B., 2014. A new ochratoxin a
554 biodegradation strategy using cupriavidus basilensis Or16 strain. PLoS One 9.
555 <https://doi.org/10.1371/journal.pone.0109817>
- 556 Fernández-Cruz, M.L., Mansilla, M.L., Tadeo, J.L., 2010. Mycotoxins in fruits and their
557 processed products: Analysis, occurrence and health implications. J. Adv. Res. 1, 113–
558 122. <https://doi.org/10.1016/j.jare.2010.03.002>
- 559 Gagliano, N., Donne, I.D., Torri, C., Migliori, M., Grizzi, F., Milzani, A., Filippi, C., Annoni,
560 G., Colombo, P., Costa, F., Ceva-Grimaldi, G., Bertelli, A.A.E., Giovannini, L., Gioia,
561 M., 2006. Early cytotoxic effects of ochratoxin A in rat liver: A morphological,
562 biochemical and molecular study. Toxicology 225, 214–224.
563 <https://doi.org/10.1016/j.tox.2006.06.004>
- 564 Haq, M., Gonzalez, N., Mintz, K., Jaja-Chimedza, A., De Jesus, C.L., Lydon, C., Welch, A.,
565 Berry, J.P., 2016. Teratogenicity of ochratoxin a and the degradation product, ochratoxin
566 α , in the zebrafish (*Danio rerio*) embryo model of vertebrate development. Toxins
567 (Basel). 8, 8–11. <https://doi.org/10.3390/toxins8020040>
- 568 Hathout, A.S., Aly, S.E., 2014. Biological detoxification of mycotoxins : a review 905–919.


- 569 <https://doi.org/10.1007/s13213-014-0899-7>
- 570 Hood, R.D., Naughton, M.J., Hayes, A.W., 1976. Prenatal Effects of Ochratoxin A in
571 Hamsters. *Teratology* 13, 11–14.
- 572 Karlovsky Petr, 1999. Biological Detoxification of Fungal Toxins and its Use in Plant
573 Breeding, Feed and Food Production. *Nat. Toxins* 23, 1–23.
- 574 Küster, E., Altenburger, R., 2008. Oxygen decline in biotesting of environmental samples—Is
575 there a need for consideration in the acute zebrafish embryo assay? *Environ. Toxicol. An
576 Int. J.* 23, 745–750. <https://doi.org/10.1002/tox.20377>
- 577 Li, S., Marquardt, R.R., Frohlich, A.A., Vitti, T.G., Crow, G., 1997. Pharmacokinetics of
578 ochratoxin α and its metabolites in rats. *Toxicol. Appl. Pharmacol.* 145, 82–90.
579 <https://doi.org/10.1006/taap.1997.8155>
- 580 Litvak and Jardine, 2003. Direct yolk sac volume manipulation of zebrafish embryos and the
581 relationship between offspring size and yolk sac volume. *J. Fish Biol.* 63, 388–397.
582 <https://doi.org/10.1046/j.1095-8649.2003.00161.x>
- 583 Marin, D.E., Taranu, I., 2015. Ochratoxin A and its effects on immunity. *Toxin Rev.* 34, 11–
584 20. <https://doi.org/10.3109/15569543.2014.958757>
- 585 Minaschek G., Bereiter-Hahn J., Bertholdt G., 1989. Quantitation of the Volume of Liquid
586 Injected by Means of Pressure into Cells powerful tool in cell research. The substances
587 injected include tracer substances. *Exp. Cell Res.* 183, 434–442.
- 588 Mizell, M., Romig, E.S., 1997. The aquatic vertebrate embryo as a sentinel for toxins:
589 Zebrafish embryo dechoriation and perivitelline space microinjection. *Int. J. Dev.
590 Biol.* 41, 411–423. <https://doi.org/10.1387/IJDB.9184351>
- 591 Nagel, R., 2002. DarT: The embryo test with the Zebrafish *Danio rerio*--a general model in
592 ecotoxicology and toxicology. *ALTEX* 19 Suppl 1, 38–48.
593 <https://doi.org/10.1007/s13311-013-0218-1>

- 594 O'Brien, E., Prietz, A., Dietrich, D.R., 2005. Investigation of the teratogenic potential of
595 ochratoxin A and B using the FETAX system. *Birth Defects Res. Part B - Dev. Reprod.*
596 *Toxicol.* 74, 417–423. <https://doi.org/10.1002/bdrb.20054>
- 597 Odhav, B., Naicker, V., 2002. Mycotoxins in South African traditional brewed beers. *Food*
598 *Addit. Contam.* 19, 55–61. <https://doi.org/10.1080/0265203011005342>
- 599 OECD236, 2013. *Oecd guidelines for the testing of chemicals* 1–22.
- 600 Otteneder, H., Majerus, P., 2000. Occurrence of ochratoxin A (OTA) in wines: Influence of
601 the type of wine and its geographical origin. *Food Addit. Contam.* 17, 793–798.
602 <https://doi.org/10.1080/026520300415345>
- 603 Pfohl-Leskowicz, A., Manderville, R.A., 2007. Ochratoxin A: An overview on toxicity and
604 carcinogenicity in animals and humans. *Mol. Nutr. Food Res.* 51, 61–99.
605 <https://doi.org/10.1002/mnfr.200600137>
- 606 Schubert, S., Keddig, N., Hanel, R., Kammann, U., 2014. Microinjection into zebrafish
607 embryos (*Danio rerio*) - a useful tool in aquatic toxicity testing? *Environ. Sci. Eur.* 26.
608 <https://doi.org/10.1186/s12302-014-0032-3>
- 609 Scudamore, K.A., Banks, J.N., Guy, R.C.E., 2004. Fate of ochratoxin A in the processing of
610 whole wheat grain during extrusion. *Food Addit. Contam.* 21, 488–497.
611 <https://doi.org/10.1080/02652030410001670166>
- 612 Sheikh-Zeinoddin, M., Khalesi, M., 2018. Biological detoxification of ochratoxin A in plants
613 and plant products. *Toxin Rev.* 0, 1–13. <https://doi.org/10.1080/15569543.2018.1452264>
- 614 Stoev, S.D., Denev, S.A., 2013. Porcine/chicken or human nephropathy as the result of joint
615 mycotoxins interaction. *Toxins (Basel)*. 5, 1503–1530.
616 <https://doi.org/10.3390/toxins5091503>
- 617 Strecker, R., Seiler, T.B., Hollert, H., Braunbeck, T., 2011. Oxygen requirements of zebrafish
618 (*Danio rerio*) embryos in embryo toxicity tests with environmental samples. *Comp.*

- 619 Biochem. Physiol. - C Toxicol. Pharmacol. 153, 318–327.
620 <https://doi.org/10.1016/j.cbpc.2010.12.002>
- 621 Vanhoutte, I., Audenaert, K., De Gelder, L., 2016. Biodegradation of mycotoxins: Tales from
622 known and unexplored worlds. *Front. Microbiol.* 7, 1–20.
623 <https://doi.org/10.3389/fmicb.2016.00561>
- 624 Vrabcheva, T., Usleber, E., Dietrich, R., Märtlbauer, E., 2000. Co-occurrence of ochratoxin A
625 and citrinin in cereals from bulgarian villages with a history of Balkan endemic
626 nephropathy. *J. Agric. Food Chem.* 48, 2483–2488. <https://doi.org/10.1021/jf990891y>
- 627 Walker, M.K., Hufnagle, L.C.J., Clayton, M.K., Peterson, R.E., 1992. An egg injection
628 method for assessing early life stage mortality of polychlorinated dibenzo-p-dioxins,
629 dibenzofurans, and biphenyls in rainbow trout, (*Onchorhynchus mykiss*). *Aquat.*
630 *Toxicol.* 22, 15–38.
- 631 Wiger, R., Starrmer, F.C., 1990. Effects of ochratoxins A and B on prechondrogenic
632 mesenchymal cells from chick embryo limb buds. *Toxicol. Lett.* 54, 129–134.
- 633 Xiao, H., Madhyastha, S., Marquardt, R.R., Li, S., Vodela, J.K., Frohlich, A.A., Kemppainen,
634 B.W., 1996. Toxicity of ochratoxin A, its opened lactone form and several of its analogs:
635 Structure-activity relationships. *Toxicol. Appl. Pharmacol.* 137, 182–192.
636 <https://doi.org/10.1006/taap.1996.0071>
- 637 Zabel, E.W., Cook, P.M., Peterson, R.E., 1995. Toxic equivalency factors of polychlorinated
638 dibenzo-p-dioxin, dibenzofuran and biphenyl congeners based on early life stage
639 mortality in rainbow trout (*Oncorhynchus mykiss*). *Aquat. Toxicol.* 31, 315–328.
640 [https://doi.org/10.1016/0166-445X\(94\)00075-2](https://doi.org/10.1016/0166-445X(94)00075-2)
- 641
642


643 **Tables and figures**

644



645 **Fig1 Variations in the diameter (A) and volume (B) of the injected droplet and mortality**
 646 **(C) and morphology (D) effects of control solutions.** The largest decrease in volume was
 647 detected in case of the 1.77 nL droplet size (17.51% (1.46 nL)), while the largest volume
 648 increase was seen in case of the 0.22 nL droplet size (18.18% (0.26 nL)). Droplet diameter
 649 and volume stayed within $\pm 20\%$, and no significant difference was detected between
 650 measurements. Average mortality rate of 120 hpf embryos injected with 4.17 nL was very low
 651 in all cases ((Non-inj-c (non-injected control): 0%, 20% LB: 5%, 20% LB + Acetone: 5%,
 652 ZFR (Zebrafish Ringers's solution): 5.83%). There was no significant difference between
 653 treatment groups and no malformations were detected in any case. Scale bar: 500 μm .

654




655

656 **Fig 2 Effects of the metabolites of *Cupriavidus basilensis* ÖR16 strain, injected in**
 657 **different volumes, on the mortality of zebrafish embryos at 72 (A) and 120 hpf (B).** After
 658 72 hours of exposure, statistical significant differences were observed between the non-
 659 injected control and 1.77 nL ($p < 0.05$), non-injected control and 4.17 nL ($p < 0.05$), 0.22 nL
 660 and 4.17 nL ($p < 0.01$). Lethality was below 10% in the non-injected control, 0.22 nL and
 661 0.52 nL. After 120 hours of exposure statistical significant differences were observed between
 662 the non-injected control and 1.77 nL ($p < 0.01$), non-injected control and 4.17 nL ($p < 0.01$),
 663 0.22 nL and 4.17 nL ($p < 0.001$). Mortality was below 10% in the non-injected control and
 664 0.22 nL.

665


666



667

668 **Fig 3 Effects of ochratoxin A (OTA) injected in different concentrations and volumes on**
 669 **the mortality of 72 (A) and 120 (B) hpf zebrafish embryos and the effects of 7 mg/L**
 670 **OTA injected in different volumes on the mortality of 72 (C) and 120 (D) hpf zebrafish**
 671 **embryos.** At 72 hpf, lethality results in the non-injected control were below 10%. Statistical
 672 significant differences were observed in the 0.52 nL ($p < 0.05$), 1.77 nL ($p < 0.05$) and 4.17
 673 nL ($p < 0.01$) groups compared to the non-injected control. Significant differences were
 674 detected between 0.22 nL and 1.77 nL ($p < 0.01$), 0.22 nL and 4.17 nL ($p < 0.0001$), 0.52 nL
 675 and 1.77 nL ($p < 0.0001$), 0.52 nL and 4.17 nL ($p < 0.05$) (C). At 120 hpf lethality results
 676 were below 10% in the non-injected control. Statistically significant differences were
 677 observed between the non-injected control and 0.52 nL ($p < 0.05$), 1.77 nL ($p < 0.05$) and
 678 4.17 nL ($p < 0.01$) groups. Significant differences were detected between 0.22 nL and 1.77 nL
 679 ($p < 0.01$), 0.22 nL and 4.17 nL ($p < 0.0001$), 0.52 nL and 1.77 nL ($p < 0.001$), 0.52 nL and
 680 4.17 nL ($p < 0.05$) (D).

681




682

683 **Fig 4 Ochratoxin A (OTA) degradation efficiency of *Cupravidus basiliensis* ÖR16 strain**684 **following 120 hours of incubation with 7 mg/L OTA (A) and effects of OTA degradation**685 **products injected in different volumes on the survival of zebrafish embryos at 72 (B)**686 **and 120 (right) hpf (C). At 72 hpf, no significant difference was observed between treatment**687 **groups and mortality was less than 10% in the non-injected control (Non-inj-c), 0.22 nL and**688 **0.52 nL groups. At 120 hpf, mortality was below 10% in the non-injected control. Statistical**689 **significant differences were observed between the non-injected control and 0.52 nL ($p <$** 690 **0.05), non-injected control and 1.77 nL ($p <$ 0.05), non-injected and 4.17 nL ($p <$ 0.05).**691 **Significant differences were detected between 0.22 nL and 1.77 nL ($p <$ 0.05), 0.22 nL and**692 **4.17 nL ($p <$ 0.05).**

693

694

695




696

697 **Fig 5 Effects of 7 mg/L Ochratoxin A (OTA 7 mg/L), bacterial metabolites (ÖR16) and**
 698 **OTA degradation products (degraded OTA) derived from the biodegradation**
 699 **experiment with *Cupriavidus basilensis* ÖR16 strain on the survival of 72 (A) and 120**
 700 **(B) hpf zebrafish embryos.** At 72 hpf mortality in the non-injected control was below 10%.
 701 Statistical significant differences were observed between OTA and degraded OTA ($p < 0.05$),
 702 OTA and ÖR16 ($p < 0.05$) in case of 0.52 nL, OTA and degraded OTA ($p < 0.01$), OTA and
 703 ÖR16 ($p < 0.01$) in case of 1.77 nL, and OTA and degraded OTA ($p < 0.01$), OTA and ÖR16
 704 ($p < 0.01$) in case of 4.17 nL. At 120 hpf mortality in the non-injected control was below
 705 10%. Statistical significant differences were observed between OTA and ÖR16 ($p < 0.05$) in
 706 case of 0.52 nL, OTA and degraded OTA ($p < 0.05$), OTA and ÖR16 ($p < 0.01$) in case of
 707 1.77 nL, and OTA and degraded OTA ($p < 0.001$), OTA and ÖR16 ($p < 0.01$) in case of 4.17
 708 nL.

709

710

711




712

713 **Fig 6 Effects of 7 mg/L Ochratoxin A (OTA 7 mg/L), bacterial metabolites (ÖR16) and**
 714 **OTA degradation products (Degraded OTA) derived from the biodegradation**
 715 **experiment with *Cupriavidus basilensis* ÖR16 strain on the frequency of developmental**
 716 **deformities in 72 (A) and 120 (B) hpf zebrafish embryos.** At 72 hpf, the highest frequency
 717 of morphological disorders was detected in the 7 mg/L OTA group. Statistically significant
 718 difference was only observed between the 1.77 nl OTA 7 mg/L and 1.77 nL ÖR16 ($p < 0.01$)
 719 groups. In 120 hpf embryos, the ratio of deformed embryos was the highest in the groups
 720 treated with OTA from 0.52 nL and above. Statistically significant difference was observed
 721 between OTA 7 mg/L and ÖR16 ($p < 0.01$) and OTA 7 mg/L and degraded OTA injected in
 722 1.77 nL ($p < 0.05$), OTA 7 mg/L and degraded OTA 7 mg/L and ÖR16 ($p < 0.01$) and OTA 7
 723 mg/L and degraded OTA ($p < 0.05$) injected in 4.17 nL. No significant difference was
 724 detected between the deformation frequencies in the groups injected with the bacterial
 725 metabolites and OTA degradation products.

726

727



728

729 **Fig 7 Representative development dysfunctions in zebrafish embryos following injection.**

730 Ochratoxin A (OTA 7 mg/L), bacterial metabolites (ÖR16) and OTA degradation products

731 (Degraded OTA) derived from biodegradation experiment with *Cupriavidus basilensis* ÖR16

732 strain were injected in 1.7, 1.77 and 4.17 nL volumes and disorders were examined following

733 72 and 120 hours of injection (A). Non-injected control embryos (Non inj. control) are shown

734 on Figure 8B. Scale bar: 500µm.

735

HIGHLIGHTS:

- ÖR16 degrades OTA to nontoxic products, however bacteria have intrinsic toxicity
- Toxicity differences between test solutions are detectable after 3 days of exposure
- Injection volume variations and control mortality correspond with OECD TG 236
- Microinjection is proper for qualifying the toxin-degrading properties of microbes
- The method helps in selecting the most effective, safe strains for detoxification